Concise enantiospecific, stereoselective syntheses of (+)-Crispine A and Its (-)-antipode

Journal of Organic Chemistry

Volumn 76, Issue 6, 2011, Pages 1605-1613

  Gurram, Mahender ^a   Gyimóthy, Balázs ^b   Wang, Ruifang ^a   Lam, Sang Q ^a   Ahmed, Feryan ^a   Herr, R Jason ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

^b AMRI   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIZATION REACTIONS; ENANTIOPURE; ENANTIOSPECIFIC; ISOLATED YIELD; NATURAL PRODUCTS; PROPANOATE; STEREO-SELECTIVE; STEREOSELECTIVE SYNTHESIS; TOTAL SYNTHESIS; TWO-STEP PROTOCOL;

AMINO ACIDS; CARBOXYLATION; CYCLIZATION; SYNTHESIS (CHEMICAL);

STEREOSELECTIVITY;

4 CHLORO 1,1 DIMETHOXYBUTANE; AMINO ACID; BUTANE; CRISPINE A; METHYL 2 AMINO 3 (3,4 DIMETHOXYPHENYL)PROPANOATE; NATURAL PRODUCT; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYCLIZATION; DECARBOXYLATION; DRUG ISOLATION; DRUG SYNTHESIS; ENANTIOSELECTIVITY; PICTET SPENGLER REACTION; STEREOCHEMISTRY;

BIOLOGICAL AGENTS; ISOQUINOLINES; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TYROSINE;

EID: 79953885697     PISSN: 00223263     EISSN: 15206904     Source Type: Journal    
DOI: 10.1021/jo102112k     Document Type: Article

References (99)

1. Zhang, Q. Y.; Tu, G. Z.; Zhao, Y. Y.; Cheng, T. M. Tetrahedron 2002, 58, 6795.
2. Maryanoff, B. E.; McComsey, D. F.; Gardocki, J. F.; Shank, R. P.; Costanzo, M. J.; Nortey, S. O.; Schneider, C. R.; Setler, P. E. J. Med. Chem. 1987, 30, 1433.
3. (a) Knölker, H.-J.; Agarwal, S. Tetrahedron Lett. 2005, 46, 1173.
4. (b) Meyer, N.; Opatz, T. Eur. J. Org. Chem. 2006, 3997.
5. (c) King, F. D. Tetrahedron 2007, 63, 2053.
6. (d) Bailey, K. R.; Ellis, A. J.; Reiss, R.; Snape, T. J.; Turner, N. J. Chem. Commun. 2007, 3640.
7. (e) Axford, L. C.; Holden, K. E.; Hasse, K.; Banwell, M. G.; Steglich, W.; Wagler, J.; Willis, A. C. Aust. J. Chem. 2008, 61, 80.
8. (f) Xu, F.; Simmons, B.; Reamer, R. A.; Corley, E.; Murry, J.; Tschaen, D. J. Org. Chem. 2008, 73, 312.
9. (g) Coldham, I.; Jana, S.; Watson, L.; Martin, N. G. Org. Biomol. Chem. 2009, 7, 1674.
10. (h) Chiou, W.-H.; Lin, G.-H.; Hsu, C.-C.; Chaterpaul, S. J.; Ojima, I. Org. Lett. 2009, 11, 2659.
11. (i) Adams, H.; Elsunaki, T. M.; Ojea- Jiménez, I.; Jones, S.; Meijer, A. J. H. M. J. Org. Chem. 2010, 75, 6252.
12. Yioti, E. G.; Mati, I. K.; Arvanitidis, A. G.; Massen, Z. S.; Alexandraki, E. S.; Gallos, J. K. Synthesis 2011, 142.
13. (a) Shono, T.; Hamaguchi, H.; Sasaki, M.; Fujita, S.; Nagami, K. J. Org. Chem. 1983, 48, 1621.
14. (b) Lochead, A. W.; Proctor, G. R.; Caton, M. P. L. J. Chem. Soc., Perkin Trans. 1 1984, 11, 2477.
15. (c) Schell, F. M.; Smith, A. M. Tetrahedron Lett. 1983, 24, 1883.
16. (d) Bremner, J. B.; Winzenberg, K. N. Aust. J. Chem. 1984, 37, 1203.
17. (e) Orito, K.; Matsuzaki, T.; Suginome, H.; Rodrigo, R. Heterocycles 1988, 27, 2403.
18. (a) Szawkalo, J.; Zawadzka, A.; Wojtasiewicz, K.; Leniewski, A.; Drabowicz, J.; Czarnocki, Z. Tetrahedron: Asymmetry 2005, 16, 3619.
19. (b) Wu, T. R.; Chong, J. M. J. Am. Chem. Soc. 2006, 128, 9646.
20. (c) Szawkalo, J.; Czarnocki, S. J.; Zawadzka, A.; Wojtasiewicz, K.; Leniewski, A.; Maurin, J. K.; Czarnocki, Z.; Drabowicz, J. Tetrahedron: Asymmetry 2007, 18, 406.
21. (d) Allin, S. M.; Gaskell, S. N.; Towler, J. M. R.; Page, P. C. B.; Saha, B.; McKenzie, M. J.; Martin, W. P. J. Org. Chem. 2007, 72, 8972.
22. (e) Hou, G.-H.; Xie, J.-H.; Yan, P.-C.; Zhou, Q.-L. J. Am. Chem. Soc. 2009, 131, 1366.
23. (f) Amat, M.; Elias, V.; Llor, N.; Subrizi, F.; Molins, E.; Bosch, J. Eur. J. Org. Chem. 2010, 4017.
24. (a) Kanemitsu, T.; Yamashita, Y.; Nagata, K.; Itoh, T. Heterocycles 2007, 74, 199.
25. (b) Evanno, L.; Ormala, J.; Pihko, P. M. Chem.- Eur. J. 2009, 15, 12963.
26. (c) Ellis, A. J.; Reiss, R.; Snape, T. J.; Turner, N. J. In Practical Methods for Biocatalysis and Biotransformations; Whittall, J., Sutton, P., Eds; John Wiley & Sons Ltd.: Chichester, 2010; pp 319-322.
27. (a) Okamoto, S.; Xin, T.; Fujii, S.; Takayama, Y.; Sato, F. J. Am. Chem. Soc. 2001, 123, 3462.
28. (b) Kapat, A.; Kumar, P. S.; Baskaran, S. Beilstein J. Org. Chem. 2007, 3, 49.
29. (c) Kumar, P. S.; Kapat, A.; Baskaran, S. Tetrahedron Lett. 2008, 49, 1241.
30. (d) Saber, M.; Comesse, S.; Dalla, V.; Daich, A.; Sanselme, M.; Netchitailo, P. Synlett 2010, 14, 2197.
31. Pictet, A.; Spengler, T. Ber. Dtsch. Chem. Ges. 1911, 44, 2030.
32. Tatsui, G. J. Pharm. Soc. Jpn. 1928, 48, 92.
33. (a) For the most recent reviews, see: (a) Cox, E. D.; Cook, J. M. Chem. Rev. 1995, 95, 1797.
34. (b) Larghi, E. L.; Amongero, M.; Bracca, A. B. J.; Kaufman, T. S. Arkivoc 2005, xii, 98.
35. (c) Czarnocki, Z.; Siwicka, A.; Szawkato, J. Curr. Org. Chem. 2005, 2, 301.
36. (d) Youn, S. W. Org. Prep. Proced. Intl. 2006, 38, 505.
37. For the most recent reviews, see: (a) Scott, J. D.; Williams, R. M. Chem. Rev. 2002, 102, 1669.
38. (b) Chrzanowska, M.; Rozwadowska, M. D. Chem. Rev. 2004, 104, 3341.
39. (c) Edwankar, C. R.; Edwankar, R. V.; Namjoshi, O. A.; Rallapalli, S. K.; Yang, J.; Cook, J. M. Curr. Opin. Drug Disc. Devel. 2009, 12, 752.
40. (d) Nielsen, T. E.; Meldal, M. Curr. Opin. Drug Discovert Dev. 2009, 12, 798.
41. This is the general case in which the intermediate iminium salt is linear (i.e., not cyclic), allowing the adoption of the (E)-configuration in the chairlike transition state. For examples, see: (a) Yamada, S.; Konda, M.; Shioiri, T. Tetrahedron Lett. 1972, 22, 2215.
42. (b) Massiot, G.; Mulamba, T. J. Chem. Soc., Chem. Commun. 1983, 1147.
43. (c) Domínguez, E.; Lete, E.; Badía, D.; Villa, M. J.; Castedo, L.; Domínguez, D. Tetrahedron 1987, 43, 1943.
44. Van der Eycken, J.; Bosmans, J.-P.; Van Haver, D.; Vandewalle, M.; Hulkenberg, A.; Veerman, W.; Nieuwenhuizen, R. Tetrahedron Lett. 1989, 30, 3873.
45. (e) Bailey, P. D.; Hollinshead, S. P.; McLay, N. R.; Morgan, K.; Palmer, S. J.; Prince, S. N.; Reynolds, C. D.; Wood, S. D. J. Chem. Soc., Perkin Trans. 1 1993, 431.
46. Bringmann, G.; Weirich, R.; Reuscher, H.; Jansen, J. R.; Kinzinger, L.; Ortmann, T. Liebigs Ann. Chem. 1993, 877.
47. (g) Carrillo, L.; Badía, D.; Domínguez, E.; Anakabe, E.; Osante, I.; Tellitu, I.; Vicario, J. L. J. Org. Chem. 1999, 64, 1115.
48. (h) Katritzky, A. R.; Mehta, S.; He, H.- Y. J. Org. Chem. 2001, 66, 148.
49. (i) Tang, Y. F.; Liu, Z. Z.; Chen, S. Z. Tetrahedron Lett. 2003, 44, 7091.
50. (j) Wang, Y.; Liu, Z. Z.; Chen, S. Z.; Liang, X. T. Chin. Chem. Lett. 2004, 15, 505.
51. (k) Shiraiwa, T.; Kiyoe, R. Chem. Pharm. Bull. 2005, 53, 1197.
52. (l) Liu, Z. Z.; Wang, Y.; Tang, Y. F.; Chen, S. Z.; Chen, X. G.; Li, H. Y. Bioorg. Med. Chem. Lett. 2006, 16, 1282.
53. (m) Chen, J.; Chen, X.; Zhu, J. J. Am. Chem. Soc. 2006, 128, 87.
54. (n) Aubry, S.; Pellet-Rostaing, S.; Faure, R.; Lemaire, M. J. Heterocycl. Chem. 2006, 43, 139.
55. (o) de la Figuera, N.; Fiol, S.; Fernandez, J.-C.; Forns, P.; Fernandez-Forner, D.; Albericio, F. Synlett 2006, 12, 1903.
56. (p)Aubry, S.; Pellet-Rostaing, S.; Fenet, B.; Lemaire, M. Tetrahedron Lett 2006, 47, 1319.
57. (q) Chakka, S. K.; Andersson, P. G.; Maguire, G. E. M.; Kruger, H. G.; Govender, T. Eur. J. Org. Chem. 2010, 972.
58. (r) Liao, X. W.; Dong, W. F.; Liu, W.; Guan, B. H.; Liu, Z. Z. J. Heterocycl. Chem. 2010, 47, 50.
59. (a) On the other hand, substrates that generate a cyclic intermediate iminium salt (e.g., arising from precursors where the amine moiety is tethered to the aldehyde) force the adoption of the (Z)-configuration in the transition state, leading to a preference for the formation of 1,3-trans products. For examples, see: (a) Tomioka, K.; Kubota, Y.; Koga, K. J. Chem. Soc., Chem. Commun. 1989, 1622.
60. (b) Tomioka, K.; Kubota, Y.; Koga, K. Tetrahedron 1993, 49, 1891.
61. (c) García, E.; Arrasate, S.; Ardeo, A.; Lete, E.; Sotomayor, N. Tetrahedron Lett. 2001, 42, 1511.
62. (d) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, T. A. D. Tetrahedron Lett. 2001, 42, 3943.
63. (e) Bahajaj, A. A.; Vernon, J. M.; Wilson, G. D. J. Chem. Soc., Perkin Trans. 1 2001, 1446.
64. (f) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, T. A. D.; Elsegood, M. R. J. J. Chem. Soc., Perkin Trans. 1 2001, 3029.
65. (g) Gonzalez, J. F.; de la Cuesta, E.; Avendeño, C. Tetrahedron 2004, 60, 6139.
66. (h) García, E.; Arrasate, S.; Lete, E.; Sotomayor, N. J. Org. Chem. 2005, 70, 10368.
67. (i) Nielsen, T. E.; Meldal, M. J. Comb. Chem. 2005, 7, 599.
68. (j) Aubry, S.; Pellet-Rostaing, S.; Lemaire, M. Eur. J. Org. Chem. 2007, 5212.
69. (k) Allin, S. M.; Towler, J.; Gaskell, S. N.; Saha, B.; Martin, W. P.; Page, P. C. B.; Edgar, M. Tetrahedron 2010, 66, 9538.
70. Although precursor (S)-(+)-2a was predicted to ultimately provide the opposite absolute configuration of naturally occurring crispine A, it was much less expensive and more readily available than the enantiomeric D-DOPA-derived building block (R)-(-)-2a for carrying out our efforts.(a) Tsuda, Y.; Hosoi, S.; Ishida, K.; Sangai, M. Chem. Pharm. Bull. 1994, 42, 204.
71. (b) Airiau, E.; Spangenberg, T.; Girard, N.; Schoenfelder, A.; Mann, A.; Salvadori, J.; Taddei, M. Chem. -Eur. J. 2008, 14, 10938.
72. See ref 12c and Ibañez, A. F.; Yaculiano, G. B.; Moltrasio Iglesias, G. Y. J. Heterocycl. Chem. 1989, 26, 907.
73. Variation in size for the reported cases in which the phenethylamine R-substituents affect the stereochemical outcome for 1,3-disubstituted tetrahydroisoquinolines have been limited to cases where the intermediate iminium species is cyclic (see ref 13). This effect for 1,3-disubstituted tetrahydro-ß-carbolines has been well-studied: see ref 10 and Van Linn, M. L.; Cook, J. M. J. Org. Chem. 2010, 75, 3587.
74. Nakamura, S.; Tanaka, M.; Taniguchi, T.; Uchiyama, M.; Ohwada, T. Org. Lett. 2003, 5, 2087.
75. Ishihara, K.; Fushimi, M. Org. Lett. 2006, 8, 1921.
76. For example, see ref 12j and Landoni, N.; Lesma, G.; Sacchetti, A.; Silvani, A. J. Org. Chem. 2007, 72, 9765.
77. (a) Kozikowski, A. P.; Ames, A. J. Org. Chem. 1978, 43, 2735.
78. (b) Kozikowski, A. P.; Ames, A. Tetrahedron 1985, 41, 4821.
79. (c) Kozikowski, A. P.; Tückmantel, W.; Reynolds, I. J.; Wroblewski, J. T. J. Med. Chem. 1990, 33, 1561.
80. (d) Schwartz, C. E.; Curran, D. P. J. Am. Chem. Soc. 1990, 112, 9272.
81. (a) Stojanovic, A.; Renaud, P. Synlett 1997, 181.
82. (b) Quirante, J.; Escolano, C.; Bonjoch, J. Synlett 1997, 179.
83. (c) Quirante, J.; Vila, X.; Escolano, C.; Bonjoch, J. J. Org. Chem. 2002, 67, 2323.
84. (d) Heureux, N.; Wouters, J.; Norberg, B.; Markó, I. E. Org. Biomol. Chem. 2006, 4, 3898.
85. The tactic of using a natural chiral amino acid or derivative as a template for induced asymmetry in a carbon-carbon bond forming reaction to prepare amine heterocycles, followed by excision of the R-functionality by decarboxylation through a selenyl ester intermediate, is a strategy that has found similar utility. For examples, see ref 20c and 21d and (a) Martin, S. F.; Chen, K. X.; Eary, C. T. Org. Lett. 1999, 1, 79.
86. (b) Deiters, A.; Chen, K.; Eary, C. T.; Martin, S. F. J. Am. Chem. Soc. 2003, 125, 4541.
87. (c) Allin, S. M.; Thomas, C. I.; Allard, J. E.; Doyle, K.; Elsegood, M. R. J. Tetrahedron Lett. 2004, 45, 7103.
88. (d) Allin, S. M.; Thomas, C. I.; Doyle, K.; Elsegood, M. R. J. J. Org. Chem. 2005, 70, 357.
89. (e) Allin, S. M.; Duffy, L. J.; Bulman Page, P. C.; McKee, V.; Edgar, M.; McKenzie, M. J.; Amat, M.; Bassas, O.; Santos, M. M. M.; Bosch, J. Tetrahedron Lett. 2006, 47, 5713.
90. (f) Allin, S. M.; Khera, J. S.; Witherington, J.; Elsegood, M. R. J. Tetrahedron Lett. 2006, 47, 5737.
91. (g) Allin, S. M.; Gaskell, S. N.; Elsegood, M. R. J.; Martin, W. P. Tetrahedron Lett. 2007, 48, 5669.
92. (h) Amat, M.; Santos, M. M. M.; Gómez, A. M.; Jokic, D.; Mollins, E.; Bosch, J. Org. Lett. 2007, 9, 2907.
93. (i) Amat, M.; Santos, M. M. M.; Bassas, O.; Llor, N.; Escolano, C.; Gmez-Esqu, A.; Molins, E.; Allin, S. M.; McKee, V.; Bosch, J. J. Org. Chem. 2007, 72, 5193. For other decarboxylation methods that achieve this strategy, see refs 5d, 12a, and 13f and
94. (j) Yamada, S.; Akimoto, H. Tetrahedron Lett. 1969, 36, 3105.
95. (k) Akimoto, H.; Okamura, K.; Yui, M.; Shioiri, T.; Kuramoto, M.; Kikugawa, Y.; Yamada, S. Chem. Pharm. Bull. 1974, 22, 1614.
96. (l) Konda, M.; Shioiri, T.; Yamada, S. Chem. Pharm. Bull. 1975, 23, 1025.
97. (m) Yamada, S. Y.; Tomioka, K.; Koga, K. Tetrahedron Lett. 1976, 17, 61.
98. (n) Tsuda, Y.; Hosoi, S.; Ishida, K.; Sangai, M. Chem. Pharm. Bull. 1994, 42, 204.
99. Schöllkopf, S. Tetrahedron 1983, 39, 2085. Although precursor (S)-(+)-13 was predicted to ultimately provide the opposite absolute configuration of naturally-occurring crispine A, it was much less expensive and more readily available than the enantiomeric D-DOPAderived building block (R)-(-)-14 for carrying out our efforts.